Spiro-oxindole compounds and their uses as therapeutic agents
This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
1. A compound of formula (XI):
wherein:
V is —O—, —N(CH 3 )— or —CH 2 — and Y is —N(CH 3 )— or —CH 2 —;
or V is —N(CH 3 )— or —CH 2 — and Y is —O— , —N(CH 3 )— or —CH 2 — ; and
R 14 is hydrogen, [5-(trifluoromethyl)furan-2-yl]methyl, pyridin-2-ylmethyl, [3-(trifluoromethyl)pyridin-2-yl]methyl or (2R)-tetrahydrofuran-2-ylmethyl; provided that when V is —O—, Y is not —CH 2 —;
or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 1 , or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
3. A method of treating pain in a mammal by the inhibition of ion flux through a voltage-dependent sodium channel in the mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1 , or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
4. A method of decreasing ion flux through a voltage-dependent sodium channel in a cell in a mammal, wherein the method comprises contacting the cell with a compound of claim 1 , or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
5. A method of treating hypercholesterolemia, benign prostatic hyperplasia or pruritis in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1 , or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
6. The compound of claim 1 wherein both V and Y are each —CH 2 —.
7. The compound of claim 6 selected from:
1-(diphenylmethyl)-5′,6′,7′,8′-tetrahydrospiro[indole-3,3′-naphtho[2,3-b]furan]-2(1H)-one;
5′,6′,7′,8′-tetrahydrospiro[indole-3,3′-naphtho[2,3-b]furan]-2(1H)-one; or
1-[(2R)-tetrahydrofuran-2-ylmethyl]-5′,6′,7′,8′-tetrahydrospiro[indole-3,3′-naphtho[2,3-b]furan]-2(1H)-one.
8. The compound of claim 1 wherein V is —O— and Y is —N(CH 3 )—.
9. The compound of claim 8 selected from:
1-methyl-1′-{[5-(trifluoromethyl)furan-2-yl]methyl}-2,3-dihydro-1H-spiro[furo[3,2-g][1,4]benzoxazine-8,3′-indol]-2′(1′H)-one;
1-methyl-1′-{[5-(trifluoromethyl)furan-2-yl]methyl}-2,3-dihydro-1H-spiro[furo[3,2-g][1,4]benzoxazine-8,3′-indol]-2′(1′H)-one hydrochloride;
1-methyl-1′-[(2R)-tetrahydrofuran-2-ylmethyl]-2,3-dihydro-1H-spiro[furo[3,2-g][1,4]benzoxazine-8,3′-indol]-2′(1′H)-one; or
1-methyl-1′-[(2R)-tetrahydrofuran-2-ylmethyl]-2,3-dihydro-1H-spiro[furo[3,2-g][1,4]benzoxazine-8,3′-indol]-2′(1∝H)-one hydrochloride.
10. The compound of claim 1 wherein V is —N(CH 3 )— and Y is —O—.
11. The compound of claim 10 which is 4-methyl-1′-[(2R)-tetrahydrofuran-2-ylmethyl]-3,4-dihydro-2H-spiro[furo[2,3g][1,4]benzoxazine-8,3′-indol]-2′(1′H)-one.
12. The compound of claim 1 wherein V is —CH 2 — and Y is —O—.
13. The compound of claim 12 selected from:
1′-(pyridin-2-ylmethyl)-7,8-dihydro-6H-spiro[furo[2,3-g]chromene-3,3′-indol]-2′(1′H)-one; or
1-{[3-(trifluoromethyl)pyridin-2-yl]methyl}-7,8-dihydro-6H-spiro[furo[2,3-g]chromene-3,3′-indol]-2′(1′H)-one.